Taipei Veterans General Hospital
Taipei, 11217, Taiwan
NCT Number: NCT02663063
The study aims to explore the effects of silver spike point (SSP) treatment on common symptoms including pain, breathlessness, nausea/vomiting, dry mouth etc. of terminal cancer patients.
Looking for future studies?
Notify MeThe study aims to explore the effects of silver spike point treatment on common symptoms including pain, breathlessness, nausea/vomiting, dry mouth etc. of terminal cancer patients. We will conducted a pilot study to evaluate the effects on different symptoms and then a prospective study will be conducted after validation of major effects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SSP treatment 5 times a week
Time frame: One week after treatment
Questionnaire for evaluating the severity of symptoms
Time frame: One week after treatment
Questionnaire for evaluating quality of life
Taipei Veterans General Hospital, Taiwan
Other Gov
The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan-The Second and Third Year Project.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01445483
Brain Diseases, Brain Metastasis
Bethesda, Maryland, United States
View Trial DetailsNCT01498276
Cancer, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05203614
Cancer, Neoplasms
Houston, Texas, United States
View Trial DetailsNCT04455698
Cancer, Neoplasms
Chicago, Illinois, United States
View Trial Details